Research archive for SYK

Stryker is a global leader in medical technologies with innovative products and services in surgical equipment, neurotechnology, and orthopaedics. They have been a Vestact-recommended stock since January 2014.

Stryker delivered another strong set of numbers on Tuesday, with fourth-quarter sales rising 10.7% to $6.4 billion, driven by an impressive 10.2% organic growth. This medical technology company has been a Vestact-recommended holding since January 2014.

Last week, our favourite medical devices business, Stryker, reported pleasing third-quarter numbers. Sales came in at $5.5 billion versus estimates of $5.37 billion and earnings were $2.87 per share versus $2.77. That's a solid beat.

Last week, the Wall Street Journal ran an article about the growing number of younger people having joint replacement surgeries. New knees and hips in their 40s. As a Stryker shareholder, this is an important topic.

Last week, medical device maker Stryker released results which were mostly what the market was expecting. Revenue was $5.4 billion (in-line with forecasts), earnings were $2.79 per share (a marginal beat) and forward guidance was on the mark. The market is a funny thing, matching expectations isn't exciting enough so Stryker's share price dropped slightly the next day.

Medical device company Stryker demonstrated a robust performance in the fourth quarter, with reported net sales increasing by 11.8% to $5.8 billion thanks to rising demand for elective surgeries. Stryker has been a Vestact-recommended stock since January 2014, exactly a decade ago.

Last week Stryker, our preferred stock in the medical devices industry, issued market-beating results with revenue of $4.9 billion, up 9.6% year-on-year, and earnings per share of $2.46. Even with that handy beat on revenue and profits, the share price dropped 0.8% on Friday because hip and knee replacement revenue was lower than expected.

Last week our medical technology holding Stryker reported solid numbers. Sales increased by 11.2% to $5 billion which resulted in an adjusted earnings per share increase of 12.9% to $2.54. They expect to make just over $10 a share for the full year. That puts the stock on a forward multiple of 28 times earnings. This is pretty standard for a quality operation showing consistent growth in a thriving industry.

A week ago Stryker reported strong first-quarter earnings and provided an upbeat outlook for the fiscal year. The medical device company's sales came in at $4.80 billion, up 11.8% year-over-year (or 14% in constant currency), surpassing the consensus estimate of $4.56 billion.

One of our portfolio shares traded at an all-time high yesterday - medical device maker Stryker. We added them to our recommended portfolio in late January 2014. The chart below shows what they have done since then.

After a tough 2022, this earnings season is a bit more tense than usual. Vestact-recommended medical device company Stryker reported numbers after the market's close last night, thankfully beating both top and bottom line expectations. As mentioned above, the stock rose smartly in after-hours trading.

On Monday night, Stryker, the medical device business, released their numbers for the third quarter of the year. My son had his tonsils taken out the other day. Whilst in the theatre I was pleased to see a Stryker surgical monitor (like the picture below), which was linked to Stryker equipment used to perform the surgery. All went well.

Stryker is always innovating in the medical devices arena. They recently launched the Gamma4 Hip Fracture Nailing System which according to the company does the following.

Medical device-maker Stryker has been a Vestact-recommended stock since January 2014. In that time they've made good progress, growing sales from around $10 billion a year to $18 billion. Profits have risen steadily too, and so has the share price.

We have a client who works in the medical devices industry and he sent me an update from Stryker, who are struggling with chip shortages. Stryker has to bid for these chips through a broker, and that's crimping margins. They expect this to continue throughout the year.